Interesting dialogue with good points from Matija and Mark. SGX942 is a very interesting compound that is similar to Brilacidin in that it has both anti-inflammatory and anti-infective properties. To date, however, the clinical data for SGX942 is ok but not great. Of course, we don't have any clinical data for Brilacidin-OM so clinical talk about B-OM is speculative at this point. We do know that animal studies with B-OM look amazing.
The bar is not set very high for any new therapy that can prove even slight effectiveness in preventing >Grade 3 OM. A couple weeks ago I commented that SGX942 efficacy may be limited by the relatively limited dosing regimen. #77391. Not sure what I'm missing with Soligenix's dosing rationale.
If a patient has a Groshong or some other injection port, the apparently well-tolerated injections along with low toxicity of SGX942 could allow for an expanded dosing regimen. Of course, an oral rinse is much more amenable to home treatment and there is no need for a Groshong (or other port). However, compliance with a TID rinse regimen may be challenging, especially if patients don't have a great understanding of the consequences of noncompliance.
News 
Market Data 
Discover 
